NUK - logo

Search results

Basic search    Expert search   

Currently you are NOT authorised to access e-resources NUK. For full access, REGISTER.

1 2 3 4 5
hits: 139
1.
  • Advances in neuroblastoma therapy
    MacFarland, Suzanne; Bagatell, Rochelle Current opinion in pediatrics, 02/2019, Volume: 31, Issue: 1
    Journal Article
    Peer reviewed

    Our understanding of the biologic basis of neuroblastoma, the genetic heterogeneity of this malignancy and the role of host factors has expanded significantly in recent years. In this review, we ...
Check availability
2.
  • Revised Neuroblastoma Risk ... Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
    Irwin, Meredith S; Naranjo, Arlene; Zhang, Fan F ... Journal of clinical oncology, 10/2021, Volume: 39, Issue: 29
    Journal Article
    Peer reviewed
    Open access

    Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk classification system used tumor stage as defined by ...
Full text
3.
  • Neuroblastoma Neuroblastoma
    Maris, John M, MD; Hogarty, Michael D, MD; Bagatell, Rochelle, MD ... The Lancet (British edition), 06/2007, Volume: 369, Issue: 9579
    Journal Article
    Peer reviewed

    Summary The clinical hallmark of neuroblastoma is heterogeneity, with the likelihood of cure varying widely according to age at diagnosis, extent of disease, and tumour biology. A subset of tumours ...
Full text
4.
  • Irinotecan–temozolomide wit... Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
    Mody, Rajen, MD; Naranjo, Arlene, PhD; Van Ryn, Collin, MS ... The lancet oncology, 07/2017, Volume: 18, Issue: 7
    Journal Article
    Peer reviewed
    Open access

    Summary Background Outcomes for children with relapsed and refractory neuroblastoma are dismal. The combination of irinotecan and temozolomide has activity in these patients, and its acceptable ...
Full text

PDF
5.
  • Children's Oncology Group's... Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
    Park, Julie R.; Bagatell, Rochelle; London, Wendy B. ... Pediatric blood & cancer, June 2013, Volume: 60, Issue: 6
    Journal Article
    Peer reviewed

    Estimated 5‐year survival rates for patients with non‐high‐risk and high‐risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy ...
Full text
6.
  • Altered Hsp90 function in c... Altered Hsp90 function in cancer: a unique therapeutic opportunity
    Bagatell, Rochelle; Whitesell, Luke Molecular cancer therapeutics 3, Issue: 8
    Journal Article
    Peer reviewed
    Open access

    Molecular chaperones or so-called heat shock proteins serve as central integrators of protein homeostasis within cells. In performing this function, they guide the folding, intracellular disposition, ...
Full text
7.
Full text
8.
  • A pharmacologically-based a... A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma
    Fox, Elizabeth; Busch, Christine; DeBernardo, Alexander ... Cancer chemotherapy and pharmacology, 06/2021, Volume: 87, Issue: 6
    Journal Article
    Peer reviewed

    Purpose High dose methotrexate (HDMTX) acute kidney injury (AKI) results in prolonged hospitalization and treatment delays. Using a pharmacologically-based approach, HDMTX was administered with ...
Full text
9.
  • Unintended consequences of ... Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events
    Miller, Tamara P.; Fisher, Brian T.; Getz, Kelly D. ... Pediatric blood & cancer, July 2019, Volume: 66, Issue: 7
    Journal Article
    Peer reviewed
    Open access

    Background Adverse events (AEs) on Children's Oncology Group (COG) trials are reported manually by clinical research assistants (CRAs). The Common Terminology Criteria for Adverse Events (CTCAE) was ...
Full text

PDF
10.
  • Children's Oncology Group's... Children's Oncology Group's 2023 blueprint for research: Neuroblastoma
    Bagatell, Rochelle; DuBois, Steven G.; Naranjo, Arlene ... Pediatric blood & cancer, September 2023, Volume: 70, Issue: S6
    Journal Article
    Peer reviewed
    Open access

    Neuroblastoma is the most common extra‐cranial solid tumor in children and is known for its clinical heterogeneity. A greater understanding of the biology of this disease has led to both improved ...
Full text
1 2 3 4 5
hits: 139

Load filters